ST Pharm Co.Ltd (237690) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of ST Pharm Co.Ltd KRW 50,110, price KRW 91,300, upside -45.1%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch ST Pharm Co.Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 59,476 KRW – 168,700 KRW · fair‑value band 37,583 KRW – 62,638 KRW · the 91,300 KRW price screens above the 50,110 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow ST Pharm Co.Ltd in your weekly email
Every Wednesday you see whether ST Pharm Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea.
Show more
ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It also provides oligonucleotide based products, such as antisense, siRNA, miRNA, aptamer, CpG, decoy, and other products; and monomer/phosphoramidite. In addition, the company offers generic APIs for anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppressant, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medicines, as well as MRI contrast agents. Further, it provides 2nd battery, electronic materials, and polymer catalysts. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 and is based in Seoul, South Korea.
Stock analysis
ST Pharm Co.Ltd (237690) currently trades at 91,300 KRW, while our model-based Fair Value estimate is 50,110 KRW, implying the stock looks roughly 82.2% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 73,028 KRW per share, and 1 of the 15 models we run sit above the 91,300 KRW price.
Bear case: the Asset-Based group reads lowest at 21,313 KRW, and 14 of the 15 models stay below the price. Evidence for this calculation is medium.
Scenario range: 37,583 KRW (bear) to 62,638 KRW (bull), the price of 91,300 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
ST Pharm Co.Ltd reported revenue of 332B KRW in FY2025 versus 166B KRW in FY2021, a compound +19.0%/yr. Reported net income was 55.0B KRW in FY2025, compounding +101.9%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 2.6T KRW (≈ $1.8B) · P/S ratio 12.8 · Dividend yield 0.3% · Net margin 16.6% · Return on equity 667% · Return on assets (EBIT) 4.0% · Operating margin 4.0% · Revenue (TTM) 201B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 46% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −41% fair-value upside, at −45%, 237690 screens richer than that median.
Fair Value models
Bear 37,583 KRWFair Value 50,110 KRWBull 62,638 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+21.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.7%
Start year 2020 (pandemic). Over 10 years: +9.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+62.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+62.6%
Dividend (yield on the price)0.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.72% vs −2%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−15% → 17%
2025 sits 155% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 56 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score44 · Below median
Fair Value upside−45% · Below median
Profitability
Return on assets1% · Below median
Net margin (TTM)5% · Above median
Operating margin (TTM)4% · Below median
Growth and dividend
Revenue growth31% · Above median
Dividend yield (TTM)0.3% · Bottom 25%
Balance sheet
Debt / equity0.07× · Above median
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
EV/EBITDA0.6× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 22
FUTURE (revenue growth)100· sector 67
PAST (return on equity)0· sector 10
HEALTH (low debt)96· sector 98
DIVIDEND (yield)7· sector 29
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is ST Pharm Co.Ltd (237690) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 50,110 KRW versus a price of 91,300 KRW, about −45% upside (overvalued).
What is the fair value of 237690?
Our model-based fair value for ST Pharm Co.Ltd is 50,110 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 91,300 KRW.
What is the quality score of 237690?
ST Pharm Co.Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ST Pharm Co.Ltd (237690)?
Our model-based price target is the fair value of 50,110 KRW (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 37,583 KRW, optimistic scenario 62,638 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ST Pharm Co.Ltd stock forecast for 2026?
Our models put fair value at 50,110 KRW, about −45% upside versus a price of 91,300 KRW (overvalued). Cautious scenario 37,583 KRW, optimistic scenario 62,638 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ST Pharm Co.Ltd (237690)?
ST Pharm Co.Ltd reported trailing-twelve-month revenue of about 201B KRW (latest available figure, as of Sep 24, 2026).
Does ST Pharm Co.Ltd pay a dividend?
ST Pharm Co.Ltd currently shows a dividend yield of about 0.34% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of ST Pharm Co.Ltd (237690)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ST Pharm Co.Ltd it is 50,110 KRW per share (as of Sep 24, 2026), against a price of 91,300 KRW. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is ST Pharm Co.Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 237690 trades above its calculated fair value: price 91,300 KRW, fair value 50,110 KRW, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 237690?
No. The price is what the market pays today (91,300 KRW); the fair value is what the company's own numbers justify (50,110 KRW). For ST Pharm Co.Ltd the two are 41,190 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ST Pharm Co.Ltd worth?
The market values ST Pharm Co.Ltd at about 2.6T KRW (market capitalisation, as of Sep 24, 2026). Per share that is 91,300 KRW; our models calculate a fair value of 50,110 KRW per share.
What do the bullish and bearish scenarios say about 237690?
Our models span a range for ST Pharm Co.Ltd: cautious scenario 37,583 KRW, base 50,110 KRW, optimistic 62,638 KRW per share (as of Sep 24, 2026, price 91,300 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ST Pharm Co.Ltd (237690)?
Balance-sheet figures for ST Pharm Co.Ltd (as of Sep 24, 2026): debt of 0.07 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 237690 from its 52-week high?
ST Pharm Co.Ltd trades at 91,300 KRW, about 46% below its 52-week high of 168,700 KRW and 8% above the low of 84,700 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 50,110 KRW is for.
Which stocks are comparable to ST Pharm Co.Ltd?
From the same area (Healthcare) we also value Caregen Co, Oscotec Inc, DongKook Pharmaceutical Co, Kolon Life Science Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ST Pharm Co.Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 91,300 KRW, calculated fair value 50,110 KRW (−45%), Quality Score 44/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 237690 calculated?
We run ST Pharm Co.Ltd through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 50,110 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. ST Pharm Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ST Pharm Co.Ltd (237690)?
The closing price on Sep 23, 2026 was 91,300 KRW. Our model-based fair value is 50,110 KRW, about −45% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ST Pharm Co.Ltd right now?
The price sits above even our optimistic bull case (62,638 KRW). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of ST Pharm Co.Ltd
How large is the market capitalisation of ST Pharm Co.Ltd (237690)?
The market capitalisation of ST Pharm Co.Ltd is 2.6T KRW (≈ $1.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ST Pharm Co.Ltd (237690)?
The price-to-sales ratio of ST Pharm Co.Ltd is 12.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of ST Pharm Co.Ltd (237690)?
The dividend yield of ST Pharm Co.Ltd is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of ST Pharm Co.Ltd (237690)?
The net margin of ST Pharm Co.Ltd is 16.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ST Pharm Co.Ltd (237690)?
The return on equity (ROE) of ST Pharm Co.Ltd is 667% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ST Pharm Co.Ltd (237690)?
On an EBIT basis the return on assets of ST Pharm Co.Ltd is 4.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ST Pharm Co.Ltd (237690)?
The operating margin of ST Pharm Co.Ltd is 4.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ST Pharm Co.Ltd (237690)?
Revenue at ST Pharm Co.Ltd is growing +31.4% versus a year earlier (3y avg +10.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ST Pharm Co.Ltd (237690)?
Earnings per share at ST Pharm Co.Ltd are growing +34.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does ST Pharm Co.Ltd (237690) generate?
The free cash flow of ST Pharm Co.Ltd is −33.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ST Pharm Co.Ltd (237690) carry?
The net debt of ST Pharm Co.Ltd is 46.0B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch ST Pharm Co.Ltd in the live analysis
One click puts ST Pharm Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
